Korean Contract Research Organization (CRO) LSK Global promotes intensified pharmacovigilance in that nation as a way to more comprehensively understand the safety profile of drugs and hence Korean patient safety.
LSK Global, purported to be the largest Korean CRO, recently announced the formation of their Pharmacovigilance department in a media session led by Lee Jeong-min, a director for the company. Jeong-min emphasized the criticality of pharmacovigilance—the task of collecting and analyzing adverse reactions. They were recently highlighted by Korea Biomedical Review.
Who is LSK Global?
LSK Global positions itself as the largest full-service CRO in Korea. Founded in 2000 as Westat-Korea, they now offer end-to-end CRO services encompassing all major areas of clinical research. By June 2019, they have conducted approximately 1,106 clinical trials representing 625 registration trials and about 129 global clinical studies. They list some of the details of their Pharmacovigilance practice here.
Pharmacovigilance in Korea
South Korea has invested continuously in advancing its drug safety field over the last thirty years. It implemented a voluntary adverse drug reaction (ADR) reporting system in 1988. In 1992 they joined the World Health Organization Program for International Drug Monitoring. Active organizations promoting improved pharmacovigilance include the Pharmacovigilance Research Network, Korean Society for Pharmacoepidemiology and Risk Management and Regional Pharmacovigilance Center (RPVC). RPVCs have been important players in establishing a pharmacovigilance system in Korean by monitoring voluntary ADR reports. Starting with just three hospitals back in 2006, they have expanded to 27 hospitals nationwide. The Korea Institute of Drug Safety & Risk Management, established in 2012, oversees the decentralized national pharmacovigilance system.